文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

皮肤和黏膜利什曼病:一家地中海医院的经验。

Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital.

机构信息

Microbiology Department, La Fe University Hospital, Valencia, Spain.

Dermatology Department, La Fe University Hospital, Valencia, Spain.

出版信息

Parasit Vectors. 2020 Jan 13;13(1):24. doi: 10.1186/s13071-020-3901-1.


DOI:10.1186/s13071-020-3901-1
PMID:31931865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6958673/
Abstract

BACKGROUND: Leishmaniasis, considered by the World Health Organization as one of the most important tropical diseases, is endemic in the Mediterranean Basin. The aim of this study was to evaluate epidemiological and clinical characteristics of cutaneous (CL) and mucocutaneous leishmaniasis (MCL) in La Fe University Hospital, Valencia, Spain. The particular focus was on diagnosis techniques and clinical differences according to the immunological status of the patients. METHODS: An eleven-year retrospective observational study of CL and MCL episodes at the hospital was performed. Epidemiological, clinical and therapeutic variables of each case, together with the microbiological and anatomopathological diagnosis, were analyzed. RESULTS: A total of 42 patients were included, 30 of them were male and 28 were immunocompetent. Most of the cases (36/42) were diagnosed in the last 5 years (2013-2017). The incidence of CL and MCL increased from 3.6/100,000 (2006-2012) to 13.58/100,000 (2013-2017). The majority of the patients (37/42) exhibited CL, in 30 cases as single lesions (30/37). Ulcerative lesions were more common in immunosuppressed patients (13/14) than in immunocompetent patients (20/28), (P = 0.2302). The length of lesion presence before diagnosis was 7.36 ± 6.72 months in immunocompetent patients and 8.79 ± 6.9 months in immunosuppressed patients (P = 0.1863). Leishmania DNA detection (92.3%) was the most sensitive diagnostic technique followed by Giemsa stain (65%) and histopathological examination (53.8%). Twelve patients (12/42) had close contact with dogs or were living near to kennels, and 10 of them did not present underlying conditions. Intralesional glucantime (21/42) and liposomal amphotericin B (7/42) were the most common treatments administered in monotherapy. All patients evolved successfully and no relapse was reported. CONCLUSIONS: Some interesting clinical and epidemiological differences were found in our series between immunocompetent and immunosuppressed patients. Future studies can take these results further especially by studying patients with biological therapy. Skin biopsies combining NAAT with histological techniques are the most productive techniques for CL or MCL diagnosis.

摘要

背景:利什曼病被世界卫生组织列为最重要的热带病之一,在地中海盆地流行。本研究旨在评估西班牙巴伦西亚拉费大学医院皮肤(CL)和黏膜皮肤利什曼病(MCL)的流行病学和临床特征。特别关注根据患者的免疫状态评估诊断技术和临床差异。 方法:对医院的 CL 和 MCL 病例进行了十一年的回顾性观察研究。分析了每个病例的流行病学、临床和治疗变量,以及微生物学和解剖病理学诊断。 结果:共纳入 42 例患者,其中男性 30 例,免疫功能正常者 28 例。大多数病例(36/42)在过去 5 年(2013-2017 年)确诊。CL 和 MCL 的发病率从 3.6/100,000(2006-2012 年)增加到 13.58/100,000(2013-2017 年)。大多数患者(42/42)表现为 CL,其中 30 例为单病灶(37/37)。溃疡性病变在免疫抑制患者(13/14)中比免疫功能正常患者(20/28)更常见(P=0.2302)。免疫功能正常患者在诊断前病变存在的时间为 7.36±6.72 个月,免疫抑制患者为 8.79±6.9 个月(P=0.1863)。利什曼原虫 DNA 检测(92.3%)是最敏感的诊断技术,其次是吉姆萨染色(65%)和组织病理学检查(53.8%)。12 例(12/42)患者与狗有密切接触或居住在犬舍附近,其中 10 例无潜在疾病。局部注射葡萄糖胺(21/42)和脂质体两性霉素 B(7/42)是最常见的单一疗法。所有患者均成功康复,无复发报告。 结论:在免疫功能正常和免疫抑制患者的系列中发现了一些有趣的临床和流行病学差异。未来的研究可以进一步研究这些结果,特别是通过研究接受生物治疗的患者。联合 NAAT 与组织学技术的皮肤活检是 CL 或 MCL 诊断最有效的技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/6958673/c6c0ffcb4c8b/13071_2020_3901_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/6958673/c6c0ffcb4c8b/13071_2020_3901_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/6958673/c6c0ffcb4c8b/13071_2020_3901_Fig1_HTML.jpg

相似文献

[1]
Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital.

Parasit Vectors. 2020-1-13

[2]
Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.

Int J Infect Dis. 2020-6-4

[3]
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.

PLoS Negl Trop Dis. 2017-11-20

[4]
Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-α inhibitors.

J Dtsch Dermatol Ges. 2023-5

[5]
Successful response to liposomal amphotericin B in mucosal leishmaniasis in glans resistant to intralesional pentavalent.

Int J Dermatol. 2019-7

[6]
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.

Infection. 2013-12

[7]
Changes in the microbiological diagnosis and epidemiology of cutaneous leishmaniasis in real-time PCR era: A six-year experience in a referral center in Barcelona.

PLoS Negl Trop Dis. 2021-11

[8]
Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.

J Am Acad Dermatol. 2015-12

[9]
American mucocutaneous leishmaniasis.

Dermatol Clin. 1994-10

[10]
Cutaneous leishmaniasis: 20 years' experience in a Spanish tertiary care hospital.

Actas Dermosifiliogr. 2015-5

引用本文的文献

[1]
Stereoselective deprotonation installs an unusual -8,9 double bond during biosynthesis of the diterpene pheromone sobralene.

Chem Commun (Camb). 2025-7-11

[2]
Molecular Assays on Cutaneous Swabs as an Effective, Non-Invasive Diagnostic Technique for Cutaneous Leishmaniasis: Results from a Retrospective Study Conducted in Italy.

Trop Med Infect Dis. 2025-6-9

[3]
Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major.

Indian J Med Res. 2024-11

[4]
The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.

Pharmaceutics. 2024-2-4

[5]
Characterisation of an area of coexistent visceral and cutaneous leishmaniasis transmission in the State of Piauí, Brazil.

Mem Inst Oswaldo Cruz. 2024

[6]
Antileishmanial effects of γCdcPLI, a phospholipase A2 inhibitor from Crotalus durissus collilineatus snake serum, on Leishmania (Leishmania) amazonensis.

Mem Inst Oswaldo Cruz. 2023

[7]
Recurrent mucosal leishmaniasis of the epiglottis in an immunosuppressed patient.

IDCases. 2023-7-25

[8]
Molecular Diagnosis of Leishmaniasis in Spain: Development and Validation of Ready-To-Use Gel-Form Nested and Real-Time PCRs To Detect spp.

Microbiol Spectr. 2023-6-15

[9]
Underestimation of Human Cutaneous Leishmaniasis Caused by in an Endemic Area of the Mediterranean Basin (Balearic Islands).

Microorganisms. 2023-1-4

[10]
Laboratory diagnostics for human Leishmania infections: a polymerase chain reaction-focussed review of detection and identification methods.

Parasit Vectors. 2022-11-5

本文引用的文献

[1]
Visceral leishmaniasis and HIV coinfection: current perspectives.

HIV AIDS (Auckl). 2018-10-15

[2]
Real-time PCR applications for diagnosis of leishmaniasis.

Parasit Vectors. 2018-5-2

[3]
Detection of Leishmania spp in silvatic mammals and isolation of Leishmania (Viannia) braziliensis from Rattus rattus in an endemic area for leishmaniasis in Minas Gerais State, Brazil.

PLoS One. 2017-11-27

[4]
Cutaneous leishmaniasis associated with anti-tumour necrosis factor-α drugs: an emerging disease.

Clin Exp Dermatol. 2017-4

[5]
Worldwide risk factors in leishmaniasis.

Asian Pac J Trop Med. 2016-10

[6]
Pediatric Cutaneous Leishmaniasis in an Endemic Region in Turkey: A Retrospective Analysis of 8786 Cases during 1998-2014.

PLoS Negl Trop Dis. 2016-7-14

[7]
A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies.

PLoS Negl Trop Dis. 2016-3-3

[8]
Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.

J Am Acad Dermatol. 2015-12

[9]
Cutaneous leishmaniasis: 20 years' experience in a Spanish tertiary care hospital.

Actas Dermosifiliogr. 2015-5

[10]
Mucocutaneous leishmaniasis caused by Leishmania infantum var Lombardi in an immunocompetent patient, Spain.

Enferm Infecc Microbiol Clin. 2015

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索